The paper reports that DING, a phosphatase found in human brain and derived from St. John's wort, reduces Tau phosphorylation and increases neuronal survival in PC12 cells and correlates with lower phospho‑Tau in a small postmortem human cohort.

The paper presents a high-accuracy (97.4%) deep-learning pipeline—using InceptionGAN augmentation, ConvNeXt and MaxViT feature extractors with Cross-Fusion Attention and hyperparameter optimization (Bayesian + genetic algorithms)—for classifying Alzheimer's and Parkinson's disease from brain MRI…

Small cross-sectional study of 20 Ghanaian PD patients found high rates of malnutrition (≈75%), sarcopenia (45%) and constipation (80%), low caloric/protein intake linked to lower BMI/body fat, thigh circumference inversely correlated with disease duration, and protein intake inversely correlated…

In rotenone and 6-OHDA rat models of Parkinson's, systemic uridine (30 mg/kg for 28 days) reduced peripheral lymphocyte SDH and LDH hyperactivity and serum lipid peroxides, and this effect was abolished by the mitoKATP inhibitor 5-hydroxydecanoate, implicating mitoKATP-mediated mitochondrial…

Multimodal imaging of >300 PD-spectrum participants reveals stage-dependent corticostriatal reorganization: early hyperconnectivity between the posterior caudate and primary motor cortex peaking around ~50% putaminal dopamine loss, and progressive loss of posterior putamen–posterior cortical…

Multicenter study of 108 idiopathic RBD patients found 40% discordance between striatal dopaminergic imaging and quantitative motor testing, with a motor-slowing/DAT-normal subgroup showing worse cognition and autonomic dysfunction, suggesting a more diffuse progression pattern.

Case report plus systematic review (19 patients) describing SEZ6L2 autoimmunity as a rare cause of subacute cerebellar ataxia frequently accompanied by cognitive dysfunction and parkinsonism, with ~47% showing partial improvement after immunotherapy.

A broad, up-to-date review positioning glycolysis and cell type–specific metabolic reprogramming as a central pathological axis across neurodegenerative diseases and summarizing actionable targets (e.g., PFKFB3, ANLS, microglial glycolysis), multimodal measurement methods, and therapeutic…

Postmortem analysis reveals alpha-synuclein inclusions in cerebellar oligodendrocytes, concurrent myelin rarefaction, and hypertrophy of dentate nucleus neurons in idiopathic Parkinson’s disease.

Using human iPSC-derived microglia, the study shows IFNγ reprograms microglial metabolism and lipidome toward a resolving-like phenotype that partially counteracts α-synuclein PFF-driven harmful secretome effects on human dopaminergic neurons.

Perspective proposing that hepatic stress—through bile acid–driven dysbiosis and mitochondrial antigen presentation—may expose mitochondrial antigens and elicit autoimmune responses that contribute to Parkinson's disease initiation and progression.

A narrative review linking endocannabinoid system modulation to regulation of nitrosative stress and neuroinflammation, arguing that cannabinoid-based interventions may slow progression in neurodegenerative diseases including Parkinson's disease.

This study finds significant enrichment of likely pathogenic VPS13C variants in idiopathic REM sleep behavior disorder (iRBD), especially the iRBD-first α-synucleinopathy subtype, and links carriers to worse RBD symptoms, autonomic and REM EEG abnormalities, and faster conversion to overt…

Real-world, open-label multicentre study of 50 advanced PD patients found subcutaneous foslevodopa/foscarbidopa infusion significantly improved motor function (UPDRS III), sleep and PDQ-8 quality-of-life scores with low dropout over 6–12 months across White and non-White cohorts.

A prospective cohort of Gaucher disease patients (22 baseline, 18 followed ~37 months) shows progressive subtle parkinsonism, increased non-motor symptoms including sleep disturbances, declining memory performance, high prevalence/progression of sensorineural hearing loss, and frequent multifocal…

Post-hoc analysis of a 52-week phase 3 trial showed subcutaneous foslevodopa/foscarbidopa infusion reduced OFF time and increased ON time without dyskinesia similarly in patients with and without prior DBS, with overall comparable safety but a higher rate of severe treatment-emergent adverse events…

RNA-seq of striata from rotenone-treated rats revealed several hundred DEGs including altered Ddc and Angpt2 and dysregulation of circadian genes (Per3 down, Arntl up), pointing to disrupted dopamine synthesis and clock pathways.

This study validates the 35-item PRO-PD patient-reported outcome measure (four-factor structure) as reliable, remotely deployable, and sensitive to patient-perceived longitudinal change in Parkinson's symptoms across motor and non-motor domains.

This small cross-sectional 16S study reports distinct gut and oral microbiota between symmetric and asymmetric PD—higher gut α-diversity and Desulfobacterota enrichment in symmetric PD versus more butyrate-producing bacteria in asymmetric PD, with associated predicted functional pathway differences.

A narrative review summarizing epidemiology, classification, proposed pathophysiology, and clinical management of headaches in Parkinson's disease, noting prevalence (up to ~49%), types (tension-type, migraine), links to motor fluctuations and dopaminergic therapy, and evidence from cohorts and…